Literature DB >> 8635109

Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A.

K Sundfør1, C G Tropé, T Högberg, M Onsrud, J Koern, E Simonsen, K Bertelsen, R Westberg.   

Abstract

BACKGROUND: The locoregional failure rate remains high in advanced cervical carcinoma. Chemotherapy (CT) was added to radiotherapy (RT) in order to increase disease control and to improve 5-year survival.
METHODS: CT + RT included cisplatin administered 100mg/m2, d.1 plus 5-fluorouracil 1000 mg/m2 D.1 to 5, ci (120 hrs), q every 3rd week for 3 cycles, followed by RT. RT included external beam irradiation 64.8 Gy in 1.8 Gy fractions, five days a week, by 4-field box technique. The median follow-up was 46 months. Ninety-four patients were evaluable for survival, 47 in the CT + RT group and 47 in the RT group. Ninety-two patients were evaluable for response. Known prognostic factors were equally distributed between the two groups.
RESULTS: Of the 43 patients evaluable before RT, 31 (72%) achieved a partial or complete response after CT alone. After RT, 52 patients attained a complete response, 25 in the CT + RT group and 27 in the RT-group. Sixty-three patients developed distant metastases or local relapse, 30 in the CT + RT group and 33 in the RT group. In the CT + RT group 6 of the 9 patients with metastases also had local progression at relapse, in the RT group, 7 of 17 patients. The survival rates for the two groups are not statistically different. Thirty-seven patients are alive, 29 have no evidence of disease. Fifty-seven have died, 29 in the CT + RT group and 28 in the RT group. Fifty-four deaths were related to cancer, and 3 to therapy.
CONCLUSIONS: Sequential CT and RT did not improve the survival, local control, or metastasis rate compared with RT alone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8635109     DOI: 10.1002/(SICI)1097-0142(19960601)77:11<2371::AID-CNCR28>3.0.CO;2-T

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

Review 1.  Management of gynaecological cancers.

Authors:  A Melville; A Eastwood; J Kleijnen; H Kitchener; P Martin-Hirsch; L Nelson
Journal:  Qual Health Care       Date:  1999-12

2.  Oxidant/anti-oxidant dynamics in patients with advanced cervical cancer: correlation with treatment response.

Authors:  Alpana Sharma; Medha Rajappa; Abhigyan Satyam; Manoj Sharma
Journal:  Mol Cell Biochem       Date:  2010-03-31       Impact factor: 3.396

Review 3.  Current opinion in cervix carcinoma.

Authors:  Silvia Rodríguez Villalba; Carmen Díaz-Caneja Planell; José Manuel Cervera Grau
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

4.  Neoadjuvant intraarterial chemotherapy for stage IIB-IIIB cervical cancer in Japanese women.

Authors:  Shoji Kaku; Kentaro Takahashi; Yoshitaka Murakami; Shirou Wakinoue; Tetsuya Nakagawa; Yoshihiko Shimizu; Nobuyuki Kita; Yoichi Noda; Takashi Murakami
Journal:  Exp Ther Med       Date:  2010-07-01       Impact factor: 2.447

5.  Radiation therapy versus surgery for patients with cervical squamous cell carcinoma who have undergone neoadjuvant chemotherapy revisited.

Authors:  Yu Furuta; Yukiharu Todo; Hiroyuki Yamazaki; Chisa Shimada; Sho Takeshita; Kazuhira Okamoto; Hidenori Kato
Journal:  Int J Clin Oncol       Date:  2017-09-19       Impact factor: 3.402

6.  A critical overview of concurrent chemoradiotherapy in cervical cancer.

Authors:  Juan E Sardi; María A Boixadera; Juan J Sardi
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

Review 7.  Neoadjuvant chemotherapy in woman with early or locally advanced cervical cancer.

Authors:  Marcela de la Torre
Journal:  Rep Pract Oncol Radiother       Date:  2018-10-13

8.  Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.

Authors:  T Sugiyama; T Nishida; S Kumagai; S Nishio; K Fujiyoshi; N Okura; M Yakushiji; M Hiura; N Umesaki
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

9.  Timing of cisplatin administration for chemoradiotherapy in transgenic mice bearing lens tumors.

Authors:  Shoji Kaku; Norichika Ushioda; Hiroshi Ishii; Takashi Murakami; Kentaro Takahashi; Yuichiro Nakai; Koichiro Shimoya; Takafumi Nakamura
Journal:  Oncol Rep       Date:  2014-05-20       Impact factor: 3.906

Review 10.  Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?

Authors:  R Glynne-Jones; J Grainger; M Harrison; P Ostler; A Makris
Journal:  Br J Cancer       Date:  2006-02-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.